Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
APRE
APRE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
APRE News
Aprea Therapeutics Closes $30 Million Oversubscribed Financing
Apr 02 2026
NASDAQ.COM
Aprea Therapeutics Closes $30 Million Financing
Apr 01 2026
Newsfilter
Wedbush Reiterates Outperform Rating for Aprea Therapeutics
Mar 31 2026
NASDAQ.COM
Aprea Therapeutics Secures $30 Million Financing for APR-1051 Development
Mar 30 2026
NASDAQ.COM
Aprea Therapeutics Reports Q4 2025 Financial Results
Mar 16 2026
seekingalpha
Aprea Therapeutics Reports Significant Tumor Shrinkage in Early Trial
Feb 18 2026
stocktwits
Aprea Therapeutics Reports Positive Cancer Trial Data
Feb 18 2026
Benzinga
Aprea Therapeutics Reports New Clinical Activity in APR-1051 Trial
Feb 18 2026
NASDAQ.COM
Aprea Secures New Patents to Strengthen Global IP Coverage
Feb 12 2026
Newsfilter
APREA THERAPEUTICS EXPANDS GLOBAL PATENT PORTFOLIO IN DNA DAMAGE RESPONSE (DDR) CANCER TREATMENTS, FOSTERING PIPELINE EXPANSION
Feb 12 2026
moomoo
Aprea Therapeutics Appoints New Chief Medical Advisor
Feb 04 2026
Newsfilter
Aprea Therapeutics Announces Securities Purchase Agreement
Jan 29 2026
seekingalpha
Aprea Therapeutics Reports Promising Early Results from ACESOT-1051 Trial for WEE1 Kinase Inhibitor APR-1051
Oct 24 2025
Newsfilter
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Jun 25 2025
Newsfilter
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
Mar 14 2025
NASDAQ.COM
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
Feb 28 2025
NASDAQ.COM
Show More News
